Multivariate analysis of pd-DMRs (GPX3, RBP1, SPARC, TGFBI) for OS
| Variable* . | HR . | 95% CI . | P . |
|---|---|---|---|
| SPARC methylation, high vs low | 2.6 | 1.4-4.9 | .002 |
| TGFBI methylation, high vs low | 2.4 | 1.3-4.5 | .004 |
| ISS | 1.6 | 1.1-2.4 | .008 |
| Treatment arm, intensive vs nonintensive | 2.6 | 1.6-4.4 | <.0001 |
| Variable* . | HR . | 95% CI . | P . |
|---|---|---|---|
| SPARC methylation, high vs low | 2.6 | 1.4-4.9 | .002 |
| TGFBI methylation, high vs low | 2.4 | 1.3-4.5 | .004 |
| ISS | 1.6 | 1.1-2.4 | .008 |
| Treatment arm, intensive vs nonintensive | 2.6 | 1.6-4.4 | <.0001 |
ISS, injury severity score.
Variables considered for model inclusion were: methylation (high vs low) of pd-DMRs mapping to the following genes: GPX3, RBP1, SPARC, TGFBI (all 4 pd-DMRs present together in this model); ISS (1-3), treatment arm (intensive vs nonintensive), age (10-y increase), presence vs absence of the following cytogenetic aberrations: t(4;14), t(14;16), deletion TP53, gain(1q).